Yasutsugu Nagamoto

Yasutsugu Nagamoto

Auto-generated profile, based on publicly available information

Yasutsugu Nagamoto

Division of Cardiology, Tsuchiya General Hospital, Hiroshima, Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2013 in Heart and Vessels
Verified
Journal Article
Closed access
PDF file
YNYasutsugu Nagamoto
Yasutsugu Nagamoto
TSTetsuya Shiomi
Tetsuya Shiomi
TMTaku Matsuura
Taku Matsuura
AOArihide Okahara
Arihide Okahara
KTKaoru Takegami
Kaoru Takegami
KHKiyoshi Hayashida
Kiyoshi Hayashida

1 October 2018 in JCR: Journal of Clinical Rheumatology
Verified
Journal Article
Closed access
KYKazutoshi Yukawa
Kazutoshi Yukawa
YNYasutsugu Nagamoto
Yasutsugu Nagamoto
HWHirofumi Watanabe
Hirofumi Watanabe
MFMasamoto Funaki
Masamoto Funaki
MIMitsuhiro Iwahashi
Mitsuhiro Iwahashi
SYSeizo Yamana
Seizo Yamana
Background/Objectives: Immunosuppressant medications (ISPs) increase the occurrence of Pneumocystis jirovecii pneumonia (PCP) in rheumatoid arthritis (RA) patients. The prophylactic administration of trimethoprim/sulfamethoxazole (TMP/SMX) for PCP is effective but has serious adverse effects and so should be selectively used for patients at high risk. The aims of this study were to clarify the risk factors for PCP in RA patients and to establish the indications for administering TMP/SMX. Methods: This retrospective cohort study analyzed data from 2640 patients (2010–2014) diagnosed as having RA who had not received a prophylactic administration of TMP/SMX. The risk factors for PCP were evaluated by comparing the clinical parameters between patients with PCP (PCP group, n = 19) and those without (non-PCP group, n = 2621). Results: The PCP group was older (70 vs. 64 years), received higher doses of prednisolone (6.2 vs. 2.4 mg/d) and methotrexate (7.7 vs. 5.2 mg/wk), and had a greater number of ISPs (1.3 vs. 0.8) (p < 0.05). We stratified the PCP risk using a scoring system based on odds ratios (ORs) calculated for these parameters (methotrexate ≥6 mg/wk OR = 4.5, 1 point; age ≥65 years, OR = 3.7, 1 point; ≥2 ISPs, OR = 3.7, 1 point; prednisolone ≥5 mg/d, OR = 12.4, 3 points). The incidence of PCP among patients scoring 0 to 2 points was 0.04%; 3 to 4 points, 2.3%; and 5 points or more, 5.8%. Conclusions: The prophylactic administration of TMP/SMX for PCP is recommended for RA patients who score at least 5 points with our system.

14 February 2013 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
TYTakanori Yamaguchi
Takanori Yamaguchi
TTTakeshi Tsuchiya
Takeshi Tsuchiya
YNYasutsugu Nagamoto
Yasutsugu Nagamoto
KMKoji Miyamoto
Koji Miyamoto
KSKenji Sadamatsu
Kenji Sadamatsu
NTNaohiko Takahashi
Naohiko Takahashi

1 June 2018 in Journal of Cardiology Cases
Verified
Journal Article
Closed access
YMYuichi Morita
Yuichi Morita
TOTomokazu Okimoto
Tomokazu Okimoto
YNYasutsugu Nagamoto
Yasutsugu Nagamoto
SMShingo Mochizuki
Shingo Mochizuki
KYKazunori Yamada
Kazunori Yamada

1 August 2013 in Journal of Cardiology Cases
Verified
Journal Article
Closed access
YNYasutsugu Nagamoto
Yasutsugu Nagamoto
TSTetsuya Shiomi
Tetsuya Shiomi
TMTaku Matsuura
Taku Matsuura
AOArihide Okahara
Arihide Okahara
KIKota Inoue
Kota Inoue
KHKiyoshi Hayashida
Kiyoshi Hayashida

26 September 2017 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
YNYasutsugu Nagamoto
Yasutsugu Nagamoto
YFYuto Fujii
Yuto Fujii
YMYuichi Morita
Yuichi Morita
YUYusuke Ueda
Yusuke Ueda
KYKenichi Yamane
Kenichi Yamane
YHYasuhiko Hayashi
Yasuhiko Hayashi
Key Clinical Message: Ganglionated plexus (GP) plays an important role in the initiation and maintenance of atrial fibrillation (AF). The GP ablation has been found to be effective for AF treatment. In this case, we reported an AF case in which the pulmonary vein (PV) potentials of the anterior region of the left superior PV were eliminated by an inferior right GP ablation.